Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).Ron H.J. Mathijssen, Alex Sparreboom|PubMed|2001Cited by 752
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Geert-Jan Creemers et al.|The Lancet Oncology|2018Cited by 419
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil TherapyJan H. Beumer, Markus Joerger, Edward Chu et al.|Clinical Pharmacology & Therapeutics|2018Cited by 126